TSI and Its Relationship With Graves' Disease Relapse | Clinical Trial | StuddyBuddy@endsection TSI and Its Relationship With Graves' Disease Relapse
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05713097

TSI and Its Relationship With Graves' Disease Relapse

Conditions: Graves Disease, Immunoglobulin, Anti-Thyroid Antibodies Disorder

Sex: All
Ages: 18 Years – N/A
Enrollment: 352
Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City

Location: Vietnam

Summary

The goal of this observational study is to determine the role of TSI, as well as clinical signs and thyroid function tests in predicting Graves' disease (GD) relapse after withdrawing anti thyroid drug (ATD). The main questions it aims to answer are:To investigate the serum TSI concentration in patients with GD undergoing maintenance-dose ATD.To determine an optimal cut-off of TSI level for predicting GD relapse.To determine the role of TSI in predicting Graves' disease relapse after withdrawing ATD.

Eligibility Criteria

Inclusion Criteria:Patients diagnosed with hyperthyroidism due to Graves' disease according to the criteria of the Japan Thyroid Association.TSI: measured during the course of treatment when planning to stop medication (normal FT4 at maintenance-dose of ATD) Methimazole (MMI): at doses of ≤10 mg. Propylthiouracil (PTU): at doses of ≤200 mg.Exclusion Criteria:Hyperthyroidism due to other causesPatients who were intolerant to ATD or had serious side effects with ATD.TSIs were measured in pregnancy.Patients treated with surgery or radioactive iodine.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05713097). StuddyBuddy aggregates publicly available trial information.